Oncology and solid tumor research
Debiopharm International S.A. supports clinical studies in advanced solid tumors, with activity spanning biomarker-selected disease settings and difficult-to-treat malignancies. Its research includes uterine serous carcinoma, high-grade epithelial ovarian cancer, and other molecularly selected cancers linked to alterations such as CCNE1 amplification and FBXW7-related changes.
- Biomarker-driven oncology
- Gynecologic cancers
- Advanced solid tumors
- Molecularly selected cancer populations
The sponsor also funds studies in small cell lung cancer and advanced prostate cancer, reflecting a strong interest in malignancies with limited treatment options.
Neuro-oncology
Clinical research supported by Debiopharm includes treatment development for glioblastoma, covering both recurrent disease and newly diagnosed cases. This area places emphasis on aggressive central nervous system tumors and combinations used in the management of brain cancer.
- Glioblastoma
- Central nervous system tumors
- Recurrent brain cancer
- Newly diagnosed glioma
The portfolio shows sustained interest in neuro-oncology settings where therapeutic progress remains limited.
Endocrine disorders
Debiopharm funds clinical research in acromegaly, a hormonal disorder involving excess insulin-like growth factor 1 activity. The studies focus on patients previously treated with somatostatin analogs and on maintaining biochemical control in a chronic endocrine condition.
- Acromegaly
- Insulin-like growth factor 1 regulation
- Somatostatin analogs
- Chronic endocrine disease
This therapeutic area extends the sponsor’s research beyond oncology into long-term hormone-related disease management.
Infectious disease
The sponsor also has clinical activity in sexually transmitted infection research, indicating interest in infectious disease areas outside oncology and endocrinology. This includes studies involving STI populations and related clinical needs.
- Sexually transmitted infection
- Infectious disease
- STI populations
These studies broaden the sponsor’s clinical portfolio into communicable disease research.
Translational and biomarker-focused therapeutics
Debiopharm’s research landscape includes therapeutic programs centered on biomarker selection, pharmacokinetics, and pharmacodynamics, supporting development across multiple disease areas. Its work spans molecularly defined tumors and treatment settings where biological characteristics guide clinical investigation.
- Biomarker selection
- Pharmacokinetics
- Pharmacodynamics
- Molecularly defined tumors
This area connects the sponsor’s oncology programs with precision-medicine-oriented clinical research.
